The options are in the money which means they will be converted on 18 December. This means that the company will get some more money and holders will get a (albeit small) profit or more shares below market cost.
Agree that the share price continues to be a disappointment though.
I can't tell what deadlines the company has committed to for commercialising any of the products, particularly TAVR. To put it another way, I can't tell how many cap raises will be required to get this over the line. Does anyone have a view of our next key milestones? Half yearly report was not very informative.
Ann: Chief Medical Officer Appointment, page-21
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.65 |
Change
-0.060(0.38%) |
Mkt cap ! $300.8M | |||
| Open | High | Low | Value | Volume |
| $15.72 | $15.85 | $15.51 | $1.660M | 117.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 312 | $15.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.65 | 626 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |